Concepedia

A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical results

Emilio Bajetta, Nicoletta Zilembo, Sandro Barni, Cristina Noberasco, Antonia Martinetti, L. Ferrari, G. Schieppati, Roberto Buzzoni, Antonio Jirillo, Maurizio Amichetti,

Annals of Oncology · 1997 · 12 citations · 17 references

DOIFull text

Open access

Concepts

References

17

In Situ Estrogen Production via the Estrone Sulfatase Pathway in Breast Tumors: Relative Importance versus the Aromatase Pathway*

Steven J. Santner, Peter D. Feil, Richard J. Santen · The Journal of Clinical Endocrinology & Metabolism · 1984 · 406 citations

, , +17

Assessment of response to therapy in advanced breast cancer

J.L. Hayward, Paul P. Carbone, Jean-Claude Heuson et al. · European Journal of Cancer (1965) · 1977 · 312 citations

, , +10

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.

P. A. Goss, TJ Powles, Mitch Dowsett et al. · PubMed · 1986 · 216 citations

, , +13

Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

Mitch Dowsett, David Cunningham, Robert C. Stein et al. · PubMed · 1989 · 141 citations

, , +17

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.

R.P. Carrion, Vicente Alberola Candel, F. Calabresi et al. · PubMed · 1994 · 99 citations

, , +17